Matthew S. Gromisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew S. Gromisch has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Betsy C. Herold
Division of Pediatric Infectious Diseases at the Children’s Hospital at Montefiore and the Albert Einstein College Medicine
4 shared publications - Aakash Mahant Mahant
Department of Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
3 shared publications - Kerry Murphy
Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York
2 shared publications Agnes Colanta
Department of Pathology, Albert Einstein College of Medicine , Bronx, New York
1 shared publicationAntonio Cajigas
Department of Pathology, Albert Einstein College of Medicine , Bronx, New York
1 shared publication- Carl F. Ware
Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America
1 shared publication
Latest Publications
- 31 July 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Mucosal IgG Interacts With Herpes Simplex Virus Glycoprotein E, an Fcγ Receptor Mimetic, and Neutralizes Viral Infection: Activity Is Reduced in the Setting of Vaginal Dysbiosis
Background: Small studies have documented variable neutralizing activity of cervicovaginal lavage (CVL) against herpes simplex viruses (HSVs). This neutralizing activity is lower in women with bacterial vaginosis, a syndrome associated with HSV recurrences. However, the mechanisms have not been fully defined. Methods: We took advantage of a biobank of CVL and linked data including HSV neutralizing activity measured by plaque reduction assay, Nugent scores, and concentrations of CVL immune mediators. We fractionated CVL to enrich or deplete candidates and quantified neutralizing activity. Results: CVL reduced viral plaque formation by 40.82% ± 37.59% (mean ± SD, n = 361). Activity was independent of HSV serostatus, significantly lower in those with a Nugent score of 7 to 10 (n = 176, P < .05), and positively correlated with CVL concentrations of IgG (P = .001, n = 87) and human neutrophil peptides 1 to 3 (P < .001, n = 119). Activity was enriched in the immunoglobulin fraction but reduced when IgG, but not IgA, was depleted. Increasing concentrations of an anti–glycoprotein E monoclonal antibody overcame the neutralizing activity, suggesting that interactions between IgG Fc and glycoprotein E (gE), a viral Fc gamma receptor, contribute. Moreover, CVL had less HSV inhibitory activity against a gE-null virus. Treatment of CVL with peptide-N-glycosidase F, which cleaves IgG N-glycans, reduced HSV neutralizing activity. Conclusions: Interactions between IgG Fc and viral gE, independent of Fab specificity, contribute to cervicovaginal antiviral activity. Antiviral activity is reduced with dysbiosis, presumably reflecting lower IgG levels and differences in N-glycans that lead to decreased gE interactions. Results highlight the importance of developing and implementing strategies to protect against vaginal dysbiosis.
- 31 July 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Mucosal IgG Interacts With Herpes Simplex Virus Glycoprotein E, an Fcγ Receptor Mimetic, and Neutralizes Viral Infection: Activity Is Reduced in the Setting of Vaginal Dysbiosis
Background: Small studies have documented variable neutralizing activity of cervicovaginal lavage (CVL) against herpes simplex viruses (HSVs). This neutralizing activity is lower in women with bacterial vaginosis, a syndrome associated with HSV recurrences. However, the mechanisms have not been fully defined. Methods: We took advantage of a biobank of CVL and linked data including HSV neutralizing activity measured by plaque reduction assay, Nugent scores, and concentrations of CVL immune mediators. We fractionated CVL to enrich or deplete candidates and quantified neutralizing activity. Results: CVL reduced viral plaque formation by 40.82% ± 37.59% (mean ± SD, n = 361). Activity was independent of HSV serostatus, significantly lower in those with a Nugent score of 7 to 10 (n = 176, P < .05), and positively correlated with CVL concentrations of IgG (P = .001, n = 87) and human neutrophil peptides 1 to 3 (P < .001, n = 119). Activity was enriched in the immunoglobulin fraction but reduced when IgG, but not IgA, was depleted. Increasing concentrations of an anti–glycoprotein E monoclonal antibody overcame the neutralizing activity, suggesting that interactions between IgG Fc and glycoprotein E (gE), a viral Fc gamma receptor, contribute. Moreover, CVL had less HSV inhibitory activity against a gE-null virus. Treatment of CVL with peptide-N-glycosidase F, which cleaves IgG N-glycans, reduced HSV neutralizing activity. Conclusions: Interactions between IgG Fc and viral gE, independent of Fab specificity, contribute to cervicovaginal antiviral activity. Antiviral activity is reduced with dysbiosis, presumably reflecting lower IgG levels and differences in N-glycans that lead to decreased gE interactions. Results highlight the importance of developing and implementing strategies to protect against vaginal dysbiosis.
- Open Access
- 4 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection
Studies with a candidate vaccine deleted in glycoprotein D (ΔgD-2) for herpes simplex virus (HSV) prevention uncovered a role for herpes virus entry mediator (HVEM) in mediating antibody-dependent cell-mediated killing (ADCK) of virally-infected cells. Antibodies elicited by ΔgD-2 passively protect wild-type but not Fc gamma receptor (FcγR) or HVEM knockout (KO) mice. The goals of this study were to identify which cells mediate ADCK and the role of HVEM signaling. Using HVEM ligand and conditional cell-type specific HVEM KO mice combined with in vitro mouse and human cytolytic assays, we demonstrate that ADCK of HSV-infected cells is mediated primarily by neutrophils and requires their expression of HVEM and its ligand, LIGHT. Cytolysis is not associated with granzyme and perforin production but occurs by a trogocytosis-like pathway. Pharmacological inhibition of myosin light-chain kinase (MLCK), which mediates trogocytosis, inhibits cytolysis. Similar results were obtained when human neutrophils were cocultured with HSV-infected cells opsonized with ADCK-containing human immune serum or with breast cancer cells treated with an anti-HER2 trogocytosis mediating antibody. Killing was significantly reduced when an MLCK inhibitor or blocking antibodies to CD16a, HVEM, or LIGHT were added. Together these results define a mechanism of HVEM-enhanced FcγR-mediated neutrophil-dependent ADCK of targets cells.
- 4 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Open AccessHVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection
Studies with a candidate vaccine deleted in glycoprotein D (ΔgD-2) for herpes simplex virus (HSV) prevention uncovered a role for herpes virus entry mediator (HVEM) in mediating antibody-dependent cell-mediated killing (ADCK) of virally-infected cells. Antibodies elicited by ΔgD-2 passively protect wild-type but not Fc gamma receptor (FcγR) or HVEM knockout (KO) mice. The goals of this study were to identify which cells mediate ADCK and the role of HVEM signaling. Using HVEM ligand and conditional cell-type specific HVEM KO mice combined with in vitro mouse and human cytolytic assays, we demonstrate that ADCK of HSV-infected cells is mediated primarily by neutrophils and requires their expression of HVEM and its ligand, LIGHT. Cytolysis is not associated with granzyme and perforin production but occurs by a trogocytosis-like pathway. Pharmacological inhibition of myosin light-chain kinase (MLCK), which mediates trogocytosis, inhibits cytolysis. Similar results were obtained when human neutrophils were cocultured with HSV-infected cells opsonized with ADCK-containing human immune serum or with breast cancer cells treated with an anti-HER2 trogocytosis mediating antibody. Killing was significantly reduced when an MLCK inhibitor or blocking antibodies to CD16a, HVEM, or LIGHT were added. Together these results define a mechanism of HVEM-enhanced FcγR-mediated neutrophil-dependent ADCK of targets cells.
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e710-e719
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women Living With HIV
Background: Women with human immunodeficiency virus (HIV, WWH) experience early onset menopause and symptoms may impact antiretroviral therapy (ART) adherence. Vaginal estradiol is safe and effective for treatment of the genitourinary syndrome of menopause (GSM) but has not been studied in WWH. The study objective was to test whether vaginal estradiol would improve GSM symptoms in menopausal WWH. Methods: Menopausal WWH were randomized 1:1 to 12 weeks of open-label vaginal estradiol (n = 25) versus no treatment (n = 26). Participants had at least 1 GSM vulvovaginal symptom in the month prior (dryness, itching, irritation, soreness, or dyspareunia) and clinical atrophy. The primary outcome was difference in mean symptom severity (scale 0–3) defined by the composite vaginal symptom index (VSI) between baseline and week 12. Changes in severity of participants’ most bothersome symptom (MBS), vaginal maturation index (VMI), vaginal microbiome, and mucosal immune mediators were assessed. Results were compared by paired t test or Wilcoxon signed rank tests; a mixed effect model examined differences in VSI improvement between groups. Results: Mean age was 59 years, 78% self-reported as Black, and all were on ART. Both groups had significant reductions in VSI, however the magnitude was significantly greater in the estradiol group (P < .0001). Estradiol and younger age were associated with VSI improvement. VMI and MBS improved significantly only in the estradiol group. There were no significant changes in the microbiome or mucosal mediators. Conclusions: The favorable response to estradiol suggests that treatment perhaps initiated earlier may be beneficial for GSM in WWH and should be studied in larger clinical trials.
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e710-e719
Open AccessImpact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women Living With HIV
Background: Women with human immunodeficiency virus (HIV, WWH) experience early onset menopause and symptoms may impact antiretroviral therapy (ART) adherence. Vaginal estradiol is safe and effective for treatment of the genitourinary syndrome of menopause (GSM) but has not been studied in WWH. The study objective was to test whether vaginal estradiol would improve GSM symptoms in menopausal WWH. Methods: Menopausal WWH were randomized 1:1 to 12 weeks of open-label vaginal estradiol (n = 25) versus no treatment (n = 26). Participants had at least 1 GSM vulvovaginal symptom in the month prior (dryness, itching, irritation, soreness, or dyspareunia) and clinical atrophy. The primary outcome was difference in mean symptom severity (scale 0–3) defined by the composite vaginal symptom index (VSI) between baseline and week 12. Changes in severity of participants’ most bothersome symptom (MBS), vaginal maturation index (VMI), vaginal microbiome, and mucosal immune mediators were assessed. Results were compared by paired t test or Wilcoxon signed rank tests; a mixed effect model examined differences in VSI improvement between groups. Results: Mean age was 59 years, 78% self-reported as Black, and all were on ART. Both groups had significant reductions in VSI, however the magnitude was significantly greater in the estradiol group (P < .0001). Estradiol and younger age were associated with VSI improvement. VMI and MBS improved significantly only in the estradiol group. There were no significant changes in the microbiome or mucosal mediators. Conclusions: The favorable response to estradiol suggests that treatment perhaps initiated earlier may be beneficial for GSM in WWH and should be studied in larger clinical trials.
- Open Access
Greater Durability and Protection against Herpes Simplex Viral Disease following Immunization of Mice with Single-Cycle ΔgD-2 Compared to an Adjuvanted Glycoprotein D Protein Vaccine
Herpes simplex viruses (HSV) cause chronic infections with significant morbidity. Prior vaccines, designed to generate neutralizing antibodies (nAbs) targeting glycoprotein D (gD), failed to provide durable protection. We adopted a different strategy and evaluated a single-cycle virus deleted in gD (ΔgD-2). ΔgD-2elicits antibodies that primarily mediate antibody-dependent cell mediated cytolysis (ADCC) and provides complete protection against clinical isolates of HSV in multiple lethal mouse models. To assess durability, we vaccinated mice (2 doses administered intramuscularly) with ΔgD-2, adjuvanted recombinant gD-2 (rgD-2/Alum-MPL), or uninfected cells as a control, and quantified antibody responses over one year. Mice (n = 5/group) were lethally challenged at 2, 4, 6, 8, and 10-months post-boost. ΔgD-2-vaccinated mice elicited a durable ADCC-mediating response, which provided complete protection against challenge at all timepoints. In contrast, rgD-2/Alum-MPL elicited only nAbs, which declined significantly within 6 months, provided only partial protection at early timepoints, and no protection after 6 months. Serum sampling after viral challenge showed that infection elicited low levels of ADCC-mediating antibodies in rgD-2/Alum-MPL-vaccinated mice and boosted the nAb response, but only after 6 months. Conversely, infection significantly and consistently boosted both the ADCC and nAbs responses in ΔgD-2-vaccinated mice. Results recapitulate clinical trial outcomes with gD vaccines, highlight the importance of ADCC, and predict that ΔgD-2 will elicit durable responses in humans.
Open AccessGreater Durability and Protection against Herpes Simplex Viral Disease following Immunization of Mice with Single-Cycle ΔgD-2 Compared to an Adjuvanted Glycoprotein D Protein Vaccine
Herpes simplex viruses (HSV) cause chronic infections with significant morbidity. Prior vaccines, designed to generate neutralizing antibodies (nAbs) targeting glycoprotein D (gD), failed to provide durable protection. We adopted a different strategy and evaluated a single-cycle virus deleted in gD (ΔgD-2). ΔgD-2elicits antibodies that primarily mediate antibody-dependent cell mediated cytolysis (ADCC) and provides complete protection against clinical isolates of HSV in multiple lethal mouse models. To assess durability, we vaccinated mice (2 doses administered intramuscularly) with ΔgD-2, adjuvanted recombinant gD-2 (rgD-2/Alum-MPL), or uninfected cells as a control, and quantified antibody responses over one year. Mice (n = 5/group) were lethally challenged at 2, 4, 6, 8, and 10-months post-boost. ΔgD-2-vaccinated mice elicited a durable ADCC-mediating response, which provided complete protection against challenge at all timepoints. In contrast, rgD-2/Alum-MPL elicited only nAbs, which declined significantly within 6 months, provided only partial protection at early timepoints, and no protection after 6 months. Serum sampling after viral challenge showed that infection elicited low levels of ADCC-mediating antibodies in rgD-2/Alum-MPL-vaccinated mice and boosted the nAb response, but only after 6 months. Conversely, infection significantly and consistently boosted both the ADCC and nAbs responses in ΔgD-2-vaccinated mice. Results recapitulate clinical trial outcomes with gD vaccines, highlight the importance of ADCC, and predict that ΔgD-2 will elicit durable responses in humans.